Abstract
Erectile dysfunction (ED) affects the majority of prostate cancer (PCa) patients. Although phosphodiesterase 5 inhibitors (PDE5i) are the first-line treatment for ED and are strongly supported by evidence as safe and effective, they remain underutilised in PCa patients. Furthermore, there is a large evidence base that supports the association of PDE5i with favourable clinical outcomes in several different health conditions that are also often considered co-morbidities for men with PCa. We present this review to examine the evidence on favourable clinical outcomes associated with PDE5i use in a range of urological, cardiovascular, metabolic, and skeletal conditions. In men who have been treated for PCa, these co-morbidities are common and may even be exacerbated by treatment itself. The evidence base suggests that PDE5i could potentially co-treat several comorbidities in men treated for PCa in addition to ED, provided high-quality randomised controlled trials replicate and confirm the findings of observational studies and animal models. If validated, PDE5i may be prescribed in appropriately selected patients and exert its beneficial effects in these men post PCa treatment, not only improving health outcomes but also quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 582-592 |
| Number of pages | 11 |
| Journal | The World Journal of Men's Health |
| Volume | 44 |
| Issue number | 3 |
| Early online date | 13 Feb 2026 |
| DOIs | |
| Publication status | Published - 1 Jul 2026 |
Bibliographical note
Copyright © 2026 Korean Society for Sexual Medicine and Andrology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Erectile dysfunction
- Phosphodiesterase inhibitor
- Prostatic neoplasms
- Therapeutics
Fingerprint
Dive into the research topics of 'Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver